Methods of administering pirfenidone therapy
DC CAFCFirst Claim
Patent Images
1. A method of administering pirfenidone to a patient in need thereof comprising administering to the patient a therapeutically effective amount of pirfenidone, and avoiding concomitant use of a cytochrome P450 1A2 (CYP1A2) inhibitor that is a moderate to strong inhibitor of both (i) CYP1A2 and (ii) another CYP enzyme selected from the group consisting of CYP2C9, CYP2C19 and CYP2D6, wherein the patient is also in need of said CYP1A2 inhibitor.
2 Assignments
Litigations
0 Petitions
Accused Products
Abstract
The present invention relates to methods involving avoiding adverse drug interactions with fluvoxamine and pirfenidone or other moderate to strong inhibitors of CYP enzymes.
38 Citations
24 Claims
- 1. A method of administering pirfenidone to a patient in need thereof comprising administering to the patient a therapeutically effective amount of pirfenidone, and avoiding concomitant use of a cytochrome P450 1A2 (CYP1A2) inhibitor that is a moderate to strong inhibitor of both (i) CYP1A2 and (ii) another CYP enzyme selected from the group consisting of CYP2C9, CYP2C19 and CYP2D6, wherein the patient is also in need of said CYP1A2 inhibitor.
-
11. A method of administering pirfenidone to a patient in need thereof, wherein said patient is in need of therapy with CYP1A2 inhibitor that is a moderate to strong inhibitor of both (i) CYP1A2 and (ii) another CYP enzyme selected from the group consisting of CYP2C9, CYP2C19 and CYP2D6, comprising:
-
(a) discontinuing said CYP1A2 inhibitor and (b) administering to the patient a therapeutically effective amount of pirfenidone. - View Dependent Claims (12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)
-
-
24. A method of administering pirfenidone comprising administering to a patient with IPF pirfenidone at a total daily dose of 2403 mg per day, administered three times per day, and avoiding or discontinuing concomitant use of a CYP1A2 inhibitor that is a moderate to strong inhibitor of both (i) CYP1A2 and (ii) another CYP enzyme selected from the group consisting of CYP2C9, CYP2C19 and CYP2D6, wherein the patient is also in need of said CYP1A2 inhibitor.
Specification